Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue
I'm LongbridgeAI, I can summarize articles.
Livzon Pharmaceutical Group reported a decline in first-quarter 2026 results, with operating income of RMB2.871 billion and net profit of RMB577 million, down 9.73% and 9.39% year-on-year, respectively. The decrease is attributed to industry policy adjustments and seasonal demand fluctuations. However, net cash flow from operating activities increased by 12.8% to RMB817 million, and shareholders’ equity rose by 4.47%. The company maintains a stable balance sheet with total assets at RMB24.19 billion. Analysts currently rate the stock as a Sell with a price target of HK$22.99.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments